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Table 1. Cost beneﬁt of LAAC relative to warfarin (rounded to the nearest
100)
Value of 1 Year of Life Cost Beneﬁt at 5 Years
$10,000 -$2,300
$25,000 $1,100
$50,000 $6,700
$76,000 $12,500
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Background: The PROTECT AF study recently demonstrated that left atrial
appendage (LAA) closure with the WATCHMAN (Boston Scientiﬁc, MN) device
was superior to warfarin for primary efﬁcacy in non-valvular atrial ﬁbrillation (NV AF)
patients, cardiovascular (CV) death, and all-cause mortality based on patients with 2621
patient years (pt-yrs) of follow-up. Five year data are available on patients from
PROTECT AF and the Continued Access Protocol (CAP) registry and, taken together,
constitute the largest cohort of long term follow-up for a LAA closure device.
Methods: Roll-in and randomized device patients in PROTECT AF and enrolled
patients in CAP were combined and grouped by CHADS2 score (CHADS22¼Group
A, CHADS2>2¼Group B). Data were analyzed for the following outcomes: composite
primary efﬁcacy (stroke, systemic embolism, and CV/unknown death), stroke (ischemic
and hemorrhagic), and mortality (all-cause and CV). The event rates are presented per
100 pt-yrs of follow-up with 95% conﬁdence intervals (CI) for the intent-to-treat group.
Results: There were 556 device patients (93 roll-in ,463 randomized) in the PROTECT
AF study and 566 device patients in the CAP Registry. For the combined cohort of 1122
patients, 706 were assigned to Group A and 416 to Group B, with a mean follow-up of
3.2 (0-6.5) and 2.7 (0-5.3) years, respectively, representing an aggregate of 3503
patient-years of follow-up. Overall event rates (95% CI) are detailed in Table 1.
Conclusions: Long-term results for the LAA closure procedure using WATCHMAN
demonstrated a viable alternative to warfarin in stroke reduction for patients with NV
AF, even after 3503 patient-years of exposure. Rates were different between the 2
device groups based on CHADS2 score, but were similar to those of comparable
patients in the RE-LY trial. These results suggest LAA closure may be a viable
alternative to novel anti-coagulants with further studies needed.Table 1. Event Rates per 100 patient-years for Groups A and B
Group A:
CHADS2 2
N=706
Rate per
100 pt-yrs
Group B:
CHADS2 >2
N=416
Rate per
100 pt-yrs
RE-LY
(110 mg)
%/yr
RE-LY
(150mg)
%/yr
Average CHADS2 Score 1.6  0.5
(1.0,2.0)
3.6  0.8
(3.0, 6.0)
2.11.1 2.21.2
Primary Efﬁcacy 1.09 4.26 N/A N/A
Ischemic Stroke 0.61 2.57 1.34 0.92
Hemorrhagic Stroke 0.09 0.17 0.12 0.10
Death (CV/
unexplained)
0.48 1.67 2.43 2.28
Death (all-cause) 2.12 5.35 3.75 3.64
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Background: Stroke prevention in atrial ﬁbrillation (AF) can be managed with
anticoagulant therapy or a device-based procedure, left atrial appendage closure
(LAAC). While both are viable treatment options, warfarin is associated with ongoingJACC Vol 62/18/Suppl B j October 27–November 1, 2013 j TCT Abstracts/Orisks and costs, and LAAC is associated with procedural risks and costs. We sought to
estimate the crossover point at which the clinical beneﬁts of LAAC relative to warfarin
outweigh the additional upfront cost.
Methods: A cost beneﬁt model was constructed using clinical data from the PROTECT
AF trial of LAAC with the WATCHMAN Device versus warfarin for prevention of
stroke in AF. Disability outcomes for LAAC were estimated from PROTECT AF and
warfarin outcomes were taken from the literature. Probability of stroke and death were
compounded with age. Costs were deﬁned as the incremental cost of treatment and
procedural complications. The beneﬁts were deﬁned as the savings achieved through
reduction in stroke and mortality. US DRGs were used to assign acute treatment costs
and long-term disability costs were taken from the literature. The value of life was varied
across a range of values based on the literature andUSgovernment value of statistical life
($76,000).
Results: The cumulative cost beneﬁt of LAAC was roughly -$2,300 at 5 years
when valuing 1 year of additional life at $10,000, but achieved a positive cost
beneﬁt of $750 at year 6, with further beneﬁts accruing for each additional year of
life.Conclusions: A positive cost beneﬁt is achieved with LAAC relative to warfarin in
the early years following device implantation. This analysis quantiﬁes the long-term
cost beneﬁt of the reduction in stroke and mortality achieved with LAAC and provides
decision makers with a tool for considering the value of reduced mortality when
assessing comparative effectiveness.TCT-96
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Background: The safety and efﬁcacy of transcatheter ligation of the left atrial
appendage (LAA) with the Lariat has not been well evaluated.
Methods: This was a multicenter retrospective study of consecutive patients under-
going LAA ligation for stroke prevention in atrial ﬁbrillation. Technical success was
deﬁned as Lariat deployed with <5mm residual leak by trans-esophageal echocar-
diogram (TEE). The primary endpoint was procedural success, deﬁned as technical
success and no major complication at discharge (death, stroke, BARC type 3 or greater
bleeding, or emergent cardiac surgery).
Results: A total of 129 patients were enrolled at 7 sites. Mean age was 7210 years,
median CHADS2 and CHA2DS2VASC scores were 3 and 4, respectively, and 60%
had a prior major bleed or diathesis for bleeding. Median procedure time was 69 min
[IQR 54-91]. Procedure success was 87% and technical success 94%. There were no
procedural deaths or strokes, and the rate of major bleeding was 9.3%. Signiﬁcant
pericardial effusion occurred in 14 cases (10.8%), with 6 cases of tamponade (4.7%).
Emergent surgery was required in 2 patients (1.6%), both with right ventricular
perforation during pericardial access. Follow-up was available for 104 patients at
a median of 81 days (IQR 39-187). There were 3 deaths (2.9%), 2 strokes (1.9%), 3
signiﬁcant pericardial effusions (2.9%), and 2 signiﬁcant pleural effusions (1.9%).
Follow-up TEE was performed in 40 patients. LA thrombus was noted in 3 (7.5%), 1
having been discharged on aspirin 81mg alone, 1 on aspirin and clopidogrel, and 1 on
no therapy. Thrombus was not seen in 11 patients treated with anticoagulation
and 3 of 29 (10%) treated without (p¼0.5). Another LA thrombus was identiﬁed by
follow-up CT imaging in a patient that was non-compliant with post-discharge
anticoagulation.
Conclusions: In this ﬁrst multicenter report, the Lariat procedure was performed
in patients at high risk for stroke in whom anticoagulation was frequently contra-
indicated. Procedure success rates were acceptable. Routine imaging follow-up to
exclude thrombus appears warranted. Prospective trials are required to clarify the
optimal medical regimen post-procedure and to determine clinical efﬁcacy.RAL/Percutaneous Treatment of Non-valvular Structural Heart Disease B31
